BIOLOGICAL PHARMACY

MORE INDUSTRIES

R & D DIRECTION

NEW PRODUCTION TECHNOLOGY FOR RECOMBINANT PROTEIN DRUGS;



MODIFICATION TECHNOLOGY OF PROTEIN DRUGS, E.G. THE TECHNOLOGY USED FOR THE DEVELOPMENT OF LONG-ACTING RECOMBINANT PROTEIN DRUGS;



EXPRESSION AND PRODUCTION TECHNOLOGY OF THERAPEUTIC MONOCL ONAL ANTIBODIES AND SINGLE-CHAIN ANTIBODIES;



STABILIZING TECHNOLOGY OF PROTEIN AND ENZYME.

PRODUCTS

MOLGRAMOSTIM (RHUGM-CSF)

FILGRASTIM (RHUG -CSF)

OPRELVEKIN (RHUIL-11)

PEGINTERFERON ALFA-2B (40KD, Y-SHAPE)

ENTERPRISE ACHIEVEMENTS

SOLD IN 10 PLUS COUNTRIES



AUTHORIZED BY 30 PLUS COUNTRIES AND REGIONS FOR INVENTION PATENTS



PREPARED AND COLLABORATIVELY CALIBRATED 20+ DOMESTIC AND INTERNATIONAL PRODUCT STANDARDS

ENTERPRISE CULTURE

ENTERPRISE MISSION: COMMITTED TO THE CONTINUOUS INNOVATION OF BIOTECHNOLOGY TO PROVIDE PRODUCTS AND SERVICES FOR HUMANS

ENTERPRISE VISION: CHINA'S LEADING INTERNATIONAL BIOTECHNOLOGY ENTERPRISE

CORE VALUES: RESPONSIBILITY, FAIRNESS, PERFORMANCE, WIN-WIN SITUATION

MORE INDUSTRIES